Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts.

On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of semaglutide and trevogrumab reduced fat mass by up to 27.1%, compared to 15.7% for semaglutide monotherapy, while preserving significantly more lean muscle mass. Overall weight reduction ranged between 9.9% and 13.4% across treatment groups in the 599-patient study.

Additionally, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced that the monitoring committee recommended early crossover in its Phase 3 Optima trial of garetosmab for fibrodysplasia ossificans progressiva, after showing a 94% reduction in new bone lesions versus placebo. The company intends to expand Phase 3 testing to pediatric patients next year and submit a U.S. regulatory application for garetosmab by the end of 2025.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a global pharmaceutical company that researches, develops, manufactures, and markets treatments for a wide range of diseases, including its EYLEA injection for severe retinal disorders. It is one of the Best Widow and Orphan Stocks.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.